Monday, September 15, 2025 9/15/2025

2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

Award Number: U54CA285114
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/22/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2028

Group Awards By:

View Award Description

2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership - The United States has led the world in drug discovery for over 50 years; however, the majority of scientific ideas that progress to clinical trials frequently come from Comprehensive Cancer Centers. Unfortunately, not all local universities and colleges have the resources to take their ideas forward to drug development and clinical trials. Through a partnership between University of California, Riverside (UCR) and City of Hope Comprehensive Cancer Center (CoHCCC), we aim to develop the resources, infrastructure, and training to help 1) UCR take their scientific ideas forward to develop therapeutic agents and ultimately initiate clinical trials and 2) mentor the next generation of drug development researchers and clinical trialists. Building on our successful P20 grant, in this U54 partnership, UCR and CoHCCC aim to develop the collaborations, resources, and training programs to improve drug development throughout the entire drug development pipeline. Our goal is for this program to become a focal point for UCR and CoHCCC to mentor and train cancer biologists, therapeutic and drug development scientists, and clinical trialists. Already, our P20 has fostered joint R01 grants, K01 grants, and pre-/post-doctoral fellowships. Both institutions are highly committed - CoHCCC contributed over $800K to our P20 grant and will contribute $250K/year to ensure the success of this U54 partnership. Aim 1 will strengthen UCR’s cancer research capacity and develop the resources to increase UCR/CoHCCC’s ability to jointly develop therapeutic agents. Aim 2 will increase the capacity of UCR and CoHCCC to jointly develop drugs and improve health. Aim 3 will provide the training, opportunity, and mentorship to foster the next generation of therapeutic scientists and clinical trialists.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,356,807 )
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA AT RIVERSIDE	200 UNIVERSTY OFC BUILDING	RIVERSIDE	CA	92521	RIVERSIDE	USA	Cancer Centers Support Grants	000	3	9/8/2025	NON-COMPETING CONTINUATION	$1,356,807
														Subtotal = $1,356,807

Issue Date FY: 2024 ( Subtotal = $1,290,685 )
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA AT RIVERSIDE	200 UNIVERSTY OFC BUILDING	RIVERSIDE	CA	92521	RIVERSIDE	USA	Cancer Centers Support Grants	000	2	8/29/2024	NON-COMPETING CONTINUATION	$1,290,685
														Subtotal = $1,290,685

Issue Date FY: 2023 ( Subtotal = $1,358,485 )
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA AT RIVERSIDE	200 UNIVERSTY OFC BUILDING	RIVERSIDE	CA	92521	RIVERSIDE	USA	Cancer Centers Support Grants	000	1	9/22/2023	NEW	$1,358,485
														Subtotal = $1,358,485

Grand Total All Awards = $4,005,977

Top

All Categories

About

Search

Reports

Data Submission

Award Information

2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

Award Number: U54CA285114

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/22/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer